Study chemo drug plus immunotherapy for metastatic triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests sacituzumab govitecan (an antibody-drug medicine) with or without pembrolizumab (an immune-system therapy) in people with metastatic triple-negative breast cancer. It may help by shrinking tumors and improving immune control, especially for patients with specific tumor marker results.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed invasive breast cancer that is locally advanced and not removable or has spread (metastatic).
- Your tumor tests show estrogen and progesterone receptors are very low (≤5%) and HER2 is negative.
- Your tumor must be PD-L1 negative based on specific lab testing (either very low immune-cell PD-L1 on SP142, or low CPS on 22C3).
- You have not had chemotherapy or other cancer medicines for metastatic breast cancer before (and you must be off them for at least 28 days).
- You must be able to do a research biopsy at the start and another biopsy 3–6 weeks after starting treatment if it can be done safely.
- You must be age 18+, have good basic blood counts and organ function, and be well enough to do daily activities (ECOG 0–1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a two-drug combination (sacituzumab govitecan and pembrolizumab) versus sacituzumab govitecan alone before surgery for low-risk, triple-negative breast cancer that hasn't spread. The goal is to see which approach works better at shrinking tumors.
This trial tests a cancer antibody-drug combination plus pembrolizumab (immunotherapy) versus standard treatment. It’s for people with triple-negative breast cancer that still has invasive disease in the breast or lymph nodes after surgery and chemotherapy before surgery.
This study is testing a drug called sacituzumab govitecan (SG) for people with advanced triple-negative breast cancer who have already had other treatments. The goal is to see how well the drug works and what side effects it causes, using your tumor samples to look for clues (biomarkers).
This study tests a drug called sacituzumab govitecan (a type of antibody-drug conjugate that targets cancer cells) as the first treatment for people with advanced triple-negative breast cancer that has not been treated before. The goal is to see if it can help shrink or control the cancer.
This trial tests a drug called sacituzumab govitecan for people with newly diagnosed triple-negative breast cancer (TNBC) that hasn't been treated yet. The drug targets cancer cells directly to try to stop them from growing.
This study compares a new combination of drugs (sacituzumab govitecan and pembrolizumab) against standard chemotherapy after you have already had initial chemotherapy. The aim is to see if the new combination shrink more breast cancers before surgery in people with triple-negative breast cancer.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.